Moderna Therapeutics Norwood, Massachusetts manufacturing plant is a competitive strategic advantage to them as they race to develop and scale-up a vaccine against COVID-19.
Moderna released data from its small Phase I study of its vaccine candidate mRNA-1273 recently, that its trial conducted by the NIAID, showed results that the candidate induces antibodies at levels comparable to those found in the blood of patients who have recovered from COVID-19.
As they move to its Phase II studies, the company will be testing on over 100 patients and on its Phase III studies, to over thousands of patients.
According to the Chief Executive Officer of Moderna, Stéphane Bancel, it’s Norwood, Massachusetts manufacturing facility played a major part in the development speed of the vaccine which helped in the progress of its vaccine candidate.
He added that, If Moderna had used contract development and manufacturing organizations (CDMOs), they would not have been able to progress that fast.
The Norwood manufacturing site is 200,000 square-foot big and was opened back in July 2018. It has the capacity to develop materials for preclinical toxicology studies, Phase I and II clinical development programs, and the ability to manufacture, test and run fill/finish operations for its mRNA development candidates.